Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Obinutuzumab may also reduce the risk of immune-related conditions from treatment. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the prote

Trial Details

NCT ID
NCT06252675
Phase
PHASE2
Sponsor
University of California, San Francisco
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Obinutuzumab
  • Glofitamab
  • Pirtobrutinib
  • Tumor Imaging
  • Biospecimen Collection
  • ClonoSeq Assay
Locations (sample)
  • Davis, California, United States|38.54491,-121.74052
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Age ≥ 18 years at the time of signing the informed consent form.
  • Have a life expectancy (in the opinion of the investigator) of at least 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status \< 2 (Karnofsky \> 60%).
  • History of previously treated MCL meeting the following criteria: Relapsed after or failed to respond to at least one prior line of systemic therap…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →